NRAS mutation

WATCH: @AlexSpiraMDPhD shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma. #melsm #Oncology https://t.co/5PNRZzBpRn (@OncLive)

WATCH: @AlexSpiraMDPhD shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma. #melsm #Oncology https://t.co/CICBP59rzb (@OncLive)

🔥Response to (K)RASG12C & EGFR Inhibition in a Patient With NRASG12C-Mutated #colorectalcancer @JCOPO_ASCO https://t.co/WNcfpzgsUJ 😅good to know... 👉extension of inclusion criteria for trials to all Ras genes could be considered @myESMO @OncoAlert https://t.co/HSTjyjxsyl (@ArndtVogel)

🔥Response to (K)RASG12C & EGFR Inhibition in a Patient With NRASG12C-Mutated #colorectalcancer @JCOPO_ASCO https://t.co/WNcfpzgsUJ 😅good to know 👉extension of inclusion criteria for trials to all Ras genes could be considered @myESMO @OncoAlert https://t.co/Vu4RSrJAFR (@ArndtVogel)

WATCH: @AlexSpiraMDPhD shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma. #melsm #Oncology https://t.co/n1jCKm0JEJ (@OncLive)

Getting great information from @Benjohnson1112 about what is new in young onset #colorectalcancer from an oncology perspective! ✅YOCRC biology differs based on race and sex ✅No significant difference in KRAS, NRAS mutations in YOCRC #crcsm #ayacsm #cancer @MDAndersonNews (@ARosen380)

In a single center experience, we demonstrate that NRAS mutation in AML does not predict worse OS. KRAS was found to be a negative predictor of OS. ⁦@FQabba⁩ https://t.co/X9EGiAOSVG (@Ali_emia)

NRAS mutations are found in 15-25% of all melanoma. Has been hard to target - We report on a major advance https://t.co/YTXjqyCuIt DeBraud et al, Naporafenib and Trametinib in NRAS-Mutant Melanoma: Results of a Phase Ib, Open-Label Study (@ad1600)

What about dysplastic changes in the marrow and NRAS mutation. Doesn’t sound favorable leukemia to me. (@TalhaBadarMD)

DDX41-focused scientist here. I have heard from clinicians about cases of DDX41 AML behaving indolently. However this occurring in the presence of the NRAS mutation surprises me. Interesting case that I’d love to hear updates on. (@tchlon)

Would really be great if a direct inhibitor of major NRAS mutation(s) could be created for control of #cancers harboring these drivers like #melanoma (@sejadiMD)

An interesting study on treating #NRAS mutant #melanoma cells with sorafenib abolishes downstream #BRAF signals, leading to cell death. https://t.co/5TgUsoul7z (@Dr_Ivanoncologo)

Proliferative CMML that is R/R or intolerant to HMA and/or Hydrea. While we don’t have mutational restrictions for enrollment we anticipate responses in #RAS pathway mutant #CMML #NRAS #KRAS #CBL #PTPN11 #NF1 (@MrinalPatnaik)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers 🔗https://t.co/Jofqagy1Z0 🥼@DrJustineCohen @Caldera60373705 @BenjcRousseau @GHUMondor @IMRB_Mondor #CRCSM #GeneExpressionProfiling #BRAF (@MolOncology)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation | Nature Communications https://t.co/O9UW5MGSvU (@weldeiry)

The combination of #ribociclib and #binimetinib in a phase Ib/II study achieved antitumor activity particularly in NRAS-mutant #melanomas with concurrent genetic alterations in cell cycle regulators. https://t.co/QX0oHJNJxE @PAscierto @MPostow @jordanberlin5 (@CCR_AACR)

There are other factors besides the continuum of RIGHT 🆚 LEFT-sidedness at play when deciding an EGFR⛔️. In general won’t recommend in: 🔴EXPANDED KRAS/NRAS mutant 🔴BRAFV600E 🔴HER2-positive 🔴RIGHT if negative for the👆🏾3🧬 in 1st line. [✅Consider 2nd/3rd line]. #CRCSM #GI22 https://t.co/ZdN7BJXIOc (@pashtoonkasi)

Really nice analysis of EMD enriched for high risk cytogenetic abnormalities including INCREASED NRAS/KRAS/BRAK mutations #ash21 #mmsm by Dr Nakamoto-Matsubara (@profghjackson)

Resistance to KRAS G12Ci @Nature, shows in 43 pts treated with sotorasib: - Low allele freq mutatns in KRAS, NRAS, MRAS, BRAF - Secondary RAS/BRAF mutatns in same KRAS G12C cells - co-blockade ERK pathway may synergize with KRASG12Ci @OncoAlert #LCSM https://t.co/aDj0u0lDqA (@DrJNaidoo)

RAF1 Amplification, HRAS/NRAS mutations collectively drive ~20% of #bladdercancer and confer sensitivity to MAPK-Directed Therapeutics @RaieBekele @mouwlab @DanaFarber-comment @aravi1 https://t.co/xPsOh4HCdz @practiceupdate (@sonpavde)

2️⃣ observations #CRCSM 📌I believe this is acquired? Typically they tend to be more in this codon. If it is I’d do non-EGFR (chemo/VEGF⛔️, REGO or TAS/BEV). t1/2 usually 3-7 months. Rechallenge later. 📌@theNCI match durable activity of MEK⛔️ in 🧬61-NRAS-mutated cancers.👇🏾@AACR https://t.co/Qw8ETic6db (@pashtoonkasi)

RAF1 amplification & HRAS/NRAS activating mutations drives ~20% #bladdercancer & confers preclinical sensitivity to MAPK targeted therapy- @mouwlab @rexirex @BrighamRadOnc @broadinstitute @DanaFarber_GU @AminNassarMD @OncoBellmunt @VanAllenLab https://t.co/BsDkYiisCh (@sonpavde)

Remind us @JenSeligmann which is the drug 💊 for the FOCUS4-C #CRCSM? 💡What’s the mechanism/rationale? From the website it says KRAS/NRAS-mutant and p53➕? What else has been reported and/or will be reported soon on the other arms? #ESMO21 @myESMO @ASCO_pubs #colorectalcancer (@pashtoonkasi)

More promise in the previously untargettable targets category - belvarafenib (RAF dimer inhibitor) + cobimetinib with PR 38.5% in a mostly post-PD-1, NRAS-mutant melanoma cohort, presented by Sang Joon Shin from Yonsei U. (S. Korea) #ASCO21 (@FunchainMD)

This work suggests RAS mutant biology melanoma (NF1/NRAS mut) are a major area of unmet need in #melanoma (just like every malignancy, sigh). And to bench folks: use these co-alterations to make better preclinical models! Some of them are whack. 29/x (@alexshoushtari)

This work has directly influenced my #melanoma practice. I (and now you!) can infer a lot from knowing someone's tumor is NF1 or NRAS G12 mutant vs NRAS Q61; from a scalp primary vs trunk vs unknown primary; or M1b stage. 26/x (@alexshoushtari)

NGS report: NRAS Q61R mutation, TMB <1. #melanomadoctor (@DrBetofMDPhD)

So glad you re-tweeted! I think I just heard about this trial in a KRAS webinar today. "Refractory RAS mutated (#KRAS or #NRAS) MSS mCRC represents an unmet medical need with non-response to immune checkpoint blockade" STOPTRAFFIC-1 unforgettable name for a trial! #CRCSM (@fireflyann)

In desmoplastic melanoma- HTMB and NRaS mutation and probably UV mutation . Please check again Melanoma - https://t.co/qHQJKjdHtH (@UmutDisel)

Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma [Aug 3, 2020] Shirazi et al. @Myeloma_Doc @PNASNews https://t.co/GfvYtrsHay #mmsm #caxtx (@mtmdphd)

Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma [Aug 3, 2020] Shirazi et al. @Myeloma_Doc @PNASNews  https://t.co/g8hvEgTmsu #mmsm #caxtx (@mtmdphd)

Why are KRAS, NRAS, and BRAF mutations so common (together ~50%) in #myeloma? See our just published paper in PNAS: Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple #myeloma https://t.co/X1TSVtlgmQ (@Myeloma_Doc)

Interesting hypothesis generating observation on durable activity of MEK⛔️ in 🧬61-NRAS-mutated cancers. Not all #NRAS-mutations are alike. #AACR20 #OncoAlert #PrecisionMedicine More data from the @theNCI #Match #ClinicalTrials #CRCSM (@pashtoonkasi)